Meeting notes from the 3rd IAS Conference. Old drugs, new data.
Researchers reported on the benefits of once-daily tenofovir + FTC + efavirenz as initial therapy, described a needle-free injection system for T-20, and announced the impending availability of lopinavir/ritonavir in tablet formulation.
Hicks
Charles B
CB
D000480:Alkynes; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001262:Atenolol / Q000008:administration & dosage / Q000627:therapeutic use*; D048588:Benzoxazines; D001938:Brazil; D003226:Congresses as Topic; D003521:Cyclopropanes; D003841:Deoxycytidine / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D061466:Lopinavir; D010078:Oxazines / Q000008:administration & dosage / Q000627:therapeutic use*; D011744:Pyrimidinones / Q000008:administration & dosage; D019438:Ritonavir / Q000008:administration & dosage
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D010078:Oxazines; D011744:Pyrimidinones; D003841:Deoxycytidine; D061466:Lopinavir; D001262:Atenolol; C098320:efavirenz; D019438:Ritonavir